230 related articles for article (PubMed ID: 31848446)
1. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1.
Zhang W; Cheng J; Diao P; Wang D; Zhang W; Jiang H; Wang Y
Br J Cancer; 2020 Feb; 122(4):528-538. PubMed ID: 31848446
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
3. The JMJD3 histone demethylase inhibitor GSK-J1 ameliorates lipopolysaccharide-induced inflammation in a mastitis model.
Wang JJ; Wang X; Xian YE; Chen ZQ; Sun YP; Fu YW; Wu ZK; Li PX; Zhou ES; Yang ZT
J Biol Chem; 2022 Jun; 298(6):102017. PubMed ID: 35526564
[TBL] [Abstract][Full Text] [Related]
4. Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts.
Sanchez A; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
Cancer Genomics Proteomics; 2022; 19(3):339-349. PubMed ID: 35430567
[TBL] [Abstract][Full Text] [Related]
5. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule GSK-J1 Affects Differentiation of Specific Neuronal Subtypes in Developing Rat Retina.
Raeisossadati R; Móvio MI; Walter LT; Takada SH; Del Debbio CB; Kihara AH
Mol Neurobiol; 2019 Mar; 56(3):1972-1983. PubMed ID: 29981055
[TBL] [Abstract][Full Text] [Related]
7. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
[No Abstract] [Full Text] [Related]
8. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
9. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
10. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
11. Jumonji domain containing-3 (JMJD3) inhibition attenuates IL-1β-induced chondrocytes damage in vitro and protects osteoarthritis cartilage in vivo.
Jun Z; Xinmeng J; Yue L; Zhi W; Yan Z; Tieyi Y; Jiangan T
Inflamm Res; 2020 Jul; 69(7):657-666. PubMed ID: 32394143
[TBL] [Abstract][Full Text] [Related]
12. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
13. Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis.
Jia W; Wu W; Yang D; Xiao C; Su Z; Huang Z; Li Z; Qin M; Huang M; Liu S; Long F; Mao J; Liu X; Zhu YZ
FASEB J; 2018 Jul; 32(7):4031-4042. PubMed ID: 29481307
[TBL] [Abstract][Full Text] [Related]
14. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
[TBL] [Abstract][Full Text] [Related]
15. Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
Hu J; Wang X; Chen L; Huang M; Tang W; Zuo J; Liu YC; Shi Z; Liu R; Shen J; Xiong B
Bioorg Med Chem Lett; 2016 Feb; 26(3):721-725. PubMed ID: 26776360
[TBL] [Abstract][Full Text] [Related]
16. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
19. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
